Idiopathic Pulmonary Fibrosis
📧 Sign up to get email alerts when something new happens for Idiopathic Pulmonary Fibrosis.
Sign up freeTop drugs studied for this disease
-
EMA approval · 2026-07-30EMA Authorised: Jascayd (nerandomilast) — Boehringer Ingelheim International GmbH
EMA authorised Jascayd (nerandomilast) for idiopathic pulmonary fibrosis, awarded to Boehringer Ingelheim International GmbH.
-
EMA approval · 2026-07-21EMA Authorised: Jascayd (nerandomilast) — Boehringer Ingelheim International GmbH
Jascayd (nerandomilast) has been authorised in the EU for idiopathic pulmonary fibrosis by Boehringer Ingelheim.
-
EMA approval · 2026-07-10EMA Authorised: Esbriet (Pirfenidone) — H.A.C. Pharma
Authorised status for Esbriet (pirfenidone) in the EU for idiopathic pulmonary fibrosis and related respiratory conditions.
-
EMA approval · 2026-06-25EMA Authorised: Nintedanib Accord (nintedanib) — Accord Healthcare S.L.U.
EU authorization of Nintedanib Accord for idiopathic pulmonary fibrosis and related interstitial lung diseases, expanding treatment options …
-
FDA approval · 2026-04-02FDA Approved: NINTEDANIB — Original Application (Edenbridge Pharmaceuticals LLC.)
FDA approved the original application for a generic version of nintedanib, developed by Edenbridge Pharmaceuticals LLC.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2026-04-02FDA Approved: NINTEDANIB — Original Application (Dr. Reddy's Laboratories Inc.)
FDA approved the generic version of nintedanib from Dr. Reddy's Laboratories Inc. under an Original Application (ANDA 219283).
-
EMA approval · 2026-01-06EMA Authorised: Ofev (nintedanib) — Boehringer Ingelheim International GmbH
The European Medicines Agency authorised a label expansion for Ofev (nintedanib) to cover additional interstitial lung diseases, including s…
-
EMA approval · 2025-12-19EMA Authorised: Pirfenidone Viatris (Pirfenidone) — Viatris Limited
EMA authorised Pirfenidone Viatris as a generic version of pirfenidone for idiopathic pulmonary fibrosis in the European Union, expanding ac…
-
EMA approval · 2025-12-10EMA Authorised: Esbriet (Pirfenidone) — Roche Registration GmbH
The European Medicines Agency authorised Esbriet (pirfenidone) for idiopathic pulmonary fibrosis under Roche Registration GmbH, with decisio…
-
EMA approval · 2025-09-05EMA Authorised: Nintedanib Viatris (nintedanib) — Viatris Limited
The European Medicines Agency authorised a generic version of nintedanib (Nintedanib Viatris) for idiopathic pulmonary fibrosis and related …
-
EMA approval · 2025-08-29EMA Authorised: Nintedanib Accord (nintedanib) — Accord Healthcare S.L.U.
The EMA authorised Nintedanib Accord for indications including Idiopathic Pulmonary Fibrosis, interstitial lung diseases, systemic sclerosis…
-
FDA approval · 2025-08-11FDA Approved: PIRFENIDONE — Original Application (Aurobindo Pharma Limited)
FDA approves the original ANDA for pirfenidone from Aurobindo Pharma Limited, making a generic version of the treatment for idiopathic pulmo…
-
FDA approval · 2025-02-04FDA Approved: PIRFENIDONE — Supplemental Application (Accord Healthcare Inc.)
FDA approved a supplemental application for pirfenidone submitted by Accord Healthcare Inc., adding an approved pirfenidone product to the m…
-
FDA approval · 2024-12-18FDA Approved: PIRFENIDONE CAPSULE, 267 MG — Original Application (Macleods Pharmaceuticals Limited)
FDA approved an original ANDA for pirfenidone capsule 267 mg by Macleods Pharmaceuticals Limited.
-
FDA approval · 2024-11-26FDA Approved: PIRFENIDONE — Supplemental Application (Teva Pharmaceuticals, Inc.)
FDA approved Teva Pharmaceuticals' supplemental application for pirfenidone (ANDA 212759).
-
EMA approval · 2024-04-25EMA Authorised: Pirfenidone axunio (previously Pirfenidone AET) (Pirfenidone) — Axunio Pharma GmbH
EMA authorised Pirfenidone axunio (Pirfenidone) for idiopathic pulmonary fibrosis under Axunio Pharma GmbH.
-
FDA approval · 2024-04-12FDA Approved: PIRFENIDONE — Supplemental Application (Cipla USA Inc.)
The FDA approved Cipla USA Inc.'s supplemental application for pirfenidone.
-
FDA approval · 2024-04-12FDA Approved: PIRFENIDONE — Supplemental Application (ScieGen Pharmaceuticals, Inc.)
The FDA approved a supplemental application for pirfenidone submitted by ScieGen Pharmaceuticals, Inc., authorizing an update to the product…
-
FDA approval · 2023-12-14FDA Approved: PIRFENIDONE — Supplemental Application (ANI Pharmaceuticals, Inc.)
The FDA approved a supplemental application for pirfenidone filed by ANI Pharmaceuticals, Inc., updating the drug's approval status.
-
FDA approval · 2023-12-14FDA Approved: PIRFENIDONE — Supplemental Application (Laurus Labs Limited)
FDA approved a supplemental application for pirfenidone from Laurus Labs Limited. Pirfenidone is used to treat idiopathic pulmonary fibrosis…
-
FDA approval · 2023-09-12FDA Approved: PIRFENIDONE — Supplemental Application (Micro Labs Limited)
The FDA approved a supplemental application for a generic pirfenidone from Micro Labs Limited, authorizing the generic product's approval. T…
-
FDA approval · 2023-08-07FDA Approved: PIRFENIDONE — Supplemental Application (Amneal Pharmaceuticals NY LLC)
The FDA approved a supplemental application for pirfenidone by Amneal Pharmaceuticals NY LLC, enabling the generic version to be marketed fo…
-
FDA approval · 2023-08-07FDA Approved: PIRFENIDONE — Supplemental Application (Sandoz Inc)
FDA approved a supplemental application for pirfenidone from Sandoz Inc, enabling a generic version to enter the market.
-
FDA approval · 2023-08-07FDA Approved: PIRFENIDONE — Supplemental Application (Novadoz Pharmaceuticals LLC)
The FDA approved a supplemental application for pirfenidone filed by Novadoz Pharmaceuticals LLC.
-
FDA approval · 2023-08-07FDA Approved: PIRFENIDONE — Supplemental Application (Alembic Pharmaceuticals Limited)
FDA approved a supplemental application for pirfenidone submitted by Alembic Pharmaceuticals Limited.